Arie Belldegrun - Kite Pharma Chairman
Chairman
Dr. Arie S. Belldegrun, M.D., FACS., is Executive Chairman of the Board, President, Chief Executive Officer, Founder of the Company. He was also appointed to serve as our President and Chief Executive Officer, an interim position he held since December 2013. Dr. Belldegrun currently serves as Chairman of Arno Therapeutics, Inc., a biopharmaceutical company, a position he has held since March 2008, as Chairman of UroGen Pharma Ltd., a pharmaceutical company, a position he has held since December 2012, and as Chairman and Partner of Two River Consulting, LLC, a consulting firm, since June 2009. He served as a Director of Teva Pharmaceutical Industries Ltd., a pharmaceutical company, from March 2013 to January 2017. He also served as a Director of Nile Therapeutics, Inc., a biotechnology company, from September 2009 to November 2013 and as a Director of SonaCare Medical, LLC, a healthcare company, from October 2009 to October 2014. In 1996, he founded Agensys, Inc., a biotechnology company, and served as its founding Chairman from 1996 to 2001, and continued to serve on the board until 2007 when it was acquired by Astellas Pharma Inc. Dr. Belldegrun was also the Founding ViceChairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009 when it was acquired by Johnson Johnson. He is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and Director of the Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA in October of 1988, since 2014.
Age | 66 |
Tenure | 10 years |
Phone | 310 824-9999 |
Web | www.kitepharma.com |
Arie Belldegrun Latest Insider Activity
Tracking and analyzing the buying and selling activities of Arie Belldegrun against Kite Pharma stock is an integral part of due diligence when investing in Kite Pharma. Arie Belldegrun insider activity provides valuable insight into whether Kite Pharma is net buyers or sellers over its current business cycle. Note, Kite Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kite Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Arie Belldegrun a day ago Acquisition by Arie Belldegrun of 4710121 shares of Allogene Therapeutics subject to Rule 16b-3 | ||
Arie Belldegrun over two weeks ago Acquisition by Arie Belldegrun of 4710120 shares of Allogene Therapeutics subject to Rule 16b-3 |
Kite Pharma Management Efficiency
Kite Pharma's management efficiency ratios could be used to measure how well Kite Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 8 records | CHAIRMAN Age | ||
Clint Gartin | Morgan Stanley | N/A | |
James Gorman | Morgan Stanley | 66 | |
William Doran | SEI Investments | 83 | |
Marcelo Odebrecht | Braskem SA Class | N/A | |
Alfred West | SEI Investments | 81 | |
Marcelo Lyrio | Braskem SA Class | 55 | |
Joao Cox | Braskem SA Class | 57 | |
Ernani Carvalho | Braskem SA Class | 68 |
Management Performance
Return On Equity | -0.0063 | |||
Return On Asset | -1.0E-4 |
Kite Pharma Leadership Team
Elected by the shareholders, the Kite Pharma's board of directors comprises two types of representatives: Kite Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kite. The board's role is to monitor Kite Pharma's management team and ensure that shareholders' interests are well served. Kite Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kite Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ran Nussbaum, Independent Director | ||
Jonathan Peacock, Independent Director | ||
Shawn Tomasello, Chief Commercial Officer | ||
Jian Irish, Senior Vice President - Supply Chain | ||
Cynthia Butitta, CFO and COO | ||
Franz Humer, Director | ||
Timothy Moore, Executive Vice President - Technical Operations | ||
Jeffrey Wiezorek, Vice President - Clinical Development | ||
Ian Clark, Independent Director | ||
Steven Ruchefsky, Independent Director | ||
Joshua Kazam, Director | ||
Helen Kim, Executive Vice President - Business Development | ||
Helen MBA, Executive VP of Bus. Devel. | ||
David Bonderman, Lead Independent Director | ||
David Chang, Executive Vice President - Research and Development, Chief Medical Officer | ||
Arie Belldegrun, Executive Chairman of the Board and Presidentident, CEO, Founder | ||
Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations | ||
Owen Witte, Director | ||
Paul Jenkinson, CFO | ||
Marc Better, VP of Translation Medicine | ||
Farah Champsi, Independent Director | ||
Roy Doumani, Independent Director | ||
Rizwana Sproule, Vice President - Regulatory Affairs | ||
Margo Roberts, Chief Scientific Officer |
Kite Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kite Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0063 | |||
Return On Asset | -1.0E-4 | |||
Current Valuation | 9.5 B | |||
Shares Outstanding | 57.36 M | |||
Shares Owned By Insiders | 6.93 % | |||
Shares Owned By Institutions | 90.47 % | |||
Number Of Shares Shorted | 8.08 M | |||
Price To Earning | (25.85) X | |||
Price To Book | 14.47 X | |||
Price To Sales | 320.94 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kite Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kite Pharma's short interest history, or implied volatility extrapolated from Kite Pharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Kite Stock
If you are still planning to invest in Kite Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kite Pharma's history and understand the potential risks before investing.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |